Quarterly Operating Losses Persist Since Last Year, and R&D Pipeline Shrinks
Bukwang's Performance Declines Over 2.5 Years Under OCI: Will Q3 Bring a Turnaround?
It's been two and a half years since OCI became the largest shareholder of Bukwang Pharmaceutical, yet instead of generating synergy, Bukwang's financial performance has continued to falter. On the…